{"id":9399,"date":"2019-12-23T11:11:30","date_gmt":"2019-12-23T11:11:30","guid":{"rendered":"https:\/\/laforcedmd.com\/?p=9399"},"modified":"2022-05-03T18:06:15","modified_gmt":"2022-05-03T18:06:15","slug":"sarepta-therapeutics-announces-partnership-roche","status":"publish","type":"post","link":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/","title":{"rendered":"Sarepta Therapeutics Announces Partnership with Roche"},"content":{"rendered":"<h4 class=\"p2\">Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001<\/h4>\n<p><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-partnership-roche-territories\" target=\"_blank\" rel=\"noopener noreferrer\">Press release here<\/a><\/span><\/p>\n<h4>Quick view<\/h4>\n<ul>\n<li class=\"p2\"><i>Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States\u00a0<\/i><\/li>\n<li class=\"p2\"><i>At closing, Sarepta will receive an upfront payment of $1.15 billion, comprising $750 million in cash and $400 million in Sarepta stock, priced at $158.59 per share of common stock\u00a0<\/i><\/li>\n<li class=\"p2\"><i>Additionally, Sarepta is eligible to receive up to $1.7 billion in regulatory and sales milestones, plus royalties on net sales\u00a0<\/i><\/li>\n<li class=\"p2\"><i>Sarepta will continue to be responsible for clinical development and manufacturing of SRP-9001 with global clinical development costs shared equally with Roche\u00a0<\/i><\/li>\n<\/ul>\n<p class=\"p2\"><strong>Sarepta Therapeutics, Inc. announced that Sarepta and Roche have entered into a licensing agreement providing Roche exclusive commercial rights to <span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/musculardystrophynews.com\/raavrh74-mhck7-micro-dystrophin\/\" target=\"_blank\" rel=\"noopener noreferrer\">SRP-9001 (AAVrh74.MHCK7.micro-dystrophin)<\/a><\/span>, Sarepta\u2019s investigational <span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/musculardystrophynews.com\/gene-therapy-in-muscular-dystrophy\/\" target=\"_blank\" rel=\"noopener noreferrer\">gene therapy<\/a><\/span> for Duchenne muscular dystrophy (DMD), outside the United States. Under the agreement, Sarepta will receive $1.15 billion in an upfront payment and an equity investment; up to $1.7 billion in regulatory and sales milestones; and royalties on net sales, anticipated to be in the mid-teens. In addition, Roche and Sarepta will equally share global development expenses. Sarepta retains all rights to SRP-9001 in the United States.<\/strong><\/p>\n<p class=\"p2\">The collaboration combines Sarepta\u2019s leading gene therapy candidate for DMD with Roche\u2019s global reach, commercial presence and regulatory expertise to accelerate access to SRP-9001 for patients outside the United States. DMD is an X-linked rare degenerative neuromuscular disorder causing severe progressive muscle loss and premature death. SRP-9001, currently in clinical development for DMD, is designed to deliver the micro-dystrophin-encoding gene directly to the muscle tissue for the targeted production of the micro-dystrophin protein.\u00e7<\/p>\n<p>&nbsp;<\/p>\n<blockquote>\n<p class=\"p2\"><strong>Doug Ingram, president and chief executive officer, Sarepta &#8211;<\/strong> \u201cAs a mission-driven organization, we are inspired to partner with Roche with the goal of bringing SRP-9001 to patients outside the United States. This collaboration will not only increase the speed with which SRP-9001 could benefit DMD patients outside the United States but will also greatly expand the scope of territories within which we could potentially launch SRP-9001 and improve and save lives. In addition to the validation that comes from joining forces with Roche, this licensing agreement \u2013 one of the most significant ex-U.S. licensing transactions in biopharma \u2013 will provide Sarepta with the resources and focus to accelerate our gene therapy engine and, if successful, bring SRP-9001 to patients as quickly as possible, potentially transforming the lives of countless DMD patients across the globe.\u201d<\/p>\n<\/blockquote>\n<p>&nbsp;<\/p>\n<blockquote>\n<p class=\"p1\"><strong>James Sabry, Head of Roche Pharma Partnering &#8211;<\/strong>\u00a0 \u201cWe are excited to enter this licensing agreement with Sarepta. By working together to provide SRP-9001 to patients, we hope to fundamentally transform the lives of patients and families living with this devastating disorder for which there are currently only limited treatment options.\u201d<\/p>\n<\/blockquote>\n<p class=\"p1\"><strong>As part of the agreement, Sarepta will continue to be responsible for the global development plan and manufacturing build-out for <span class=\"s1\">SRP-9001<\/span>. Through its leading hybrid manufacturing platform, Sarepta will remain responsible for manufacturing of clinical and commercial supplies. Sarepta has also granted Roche an option to acquire ex-U.S. rights to certain future DMD-specific programs, in exchange for separate milestone and royalty considerations, and cost-sharing.<\/strong><\/p>\n<p class=\"p1\">\n<h4>About Sarepta<\/h4>\n<p>Sarepta Therapeutics, Inc., a biopharmaceutical company, is working to unlock the potential of RNA-based and gene therapy technologies for the treatment of serious and life-threatening diseases like Duchenne muscular dystrophy (DMD). Sarepta\u2019s primary focus is to rapidly advance new treatments for DMD.<\/p>\n<h4>More interesting links<\/h4>\n<ul>\n<li><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.sarepta.com\/our-pipeline\" target=\"_blank\" rel=\"noopener noreferrer\">Sarepta drug pipeline<\/a><\/span><\/li>\n<li><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"\/?page_id=8990\" target=\"_blank\" rel=\"noopener noreferrer\">Grounded in the DMD community<\/a><\/span><\/li>\n<li><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/www.sarepta.com\/\" rel=\"noopener\">Sarepta Therapeutics, Inc.<\/a><\/span><\/li>\n<li><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/musculardystrophynews.com\/raavrh74-mhck7-micro-dystrophin\/\" target=\"_blank\" rel=\"noopener noreferrer\">SRP-9001 Micro-Dystrophin <\/a><span style=\"color: #333333;\">from<\/span><\/span> Muscular Dystrophy News Today<\/li>\n<li><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"https:\/\/musculardystrophynews.com\/gene-therapy-in-muscular-dystrophy\/\" target=\"_blank\" rel=\"noopener noreferrer\">Gene Therapy<\/a><\/span><span style=\"color: #0000ff;\"><span style=\"color: #333333;\"> from<\/span><\/span> Muscular Dystrophy News Today<\/li>\n<\/ul>\n<h4 class=\"p1\">Source<\/h4>\n<p class=\"p1\">Sarepta Therapeutics, Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001 Press release here Quick view Roche obtains the exclusive right to launch and commercialize SRP-9001 outside the United States\u00a0 At closing, Sarepta will receive an upfront payment of $1.15 billion, comprising $750 [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":9405,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12],"tags":[],"class_list":["post-9399","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sarepta Therapeutics Announces Partnership with Roche - La Force dmd<\/title>\n<meta name=\"description\" content=\"Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the US for its Investigational Micro-dystrophin Gene Therapy for DMD\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarepta Therapeutics Announces Partnership with Roche - La Force dmd\" \/>\n<meta property=\"og:description\" content=\"Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the US for its Investigational Micro-dystrophin Gene Therapy for DMD\" \/>\n<meta property=\"og:url\" content=\"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/\" \/>\n<meta property=\"og:site_name\" content=\"La Force dmd\" \/>\n<meta property=\"article:published_time\" content=\"2019-12-23T11:11:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-03T18:06:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/laforcedmd.com\/wp-content\/uploads\/2019\/12\/Sarepta-Therapeutics-Announces-partnership-Roche.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"815\" \/>\n\t<meta property=\"og:image:height\" content=\"356\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marie\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marie\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/\"},\"author\":{\"name\":\"Marie\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/person\\\/aa9947f206c7912f07291299569bf4bf\"},\"headline\":\"Sarepta Therapeutics Announces Partnership with Roche\",\"datePublished\":\"2019-12-23T11:11:30+00:00\",\"dateModified\":\"2022-05-03T18:06:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/\"},\"wordCount\":612,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/Sarepta-Therapeutics-Announces-partnership-Roche.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/\",\"name\":\"Sarepta Therapeutics Announces Partnership with Roche - La Force dmd\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/Sarepta-Therapeutics-Announces-partnership-Roche.jpg\",\"datePublished\":\"2019-12-23T11:11:30+00:00\",\"dateModified\":\"2022-05-03T18:06:15+00:00\",\"description\":\"Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the US for its Investigational Micro-dystrophin Gene Therapy for DMD\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/#primaryimage\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/Sarepta-Therapeutics-Announces-partnership-Roche.jpg\",\"contentUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/Sarepta-Therapeutics-Announces-partnership-Roche.jpg\",\"width\":815,\"height\":356,\"caption\":\"Sarepta Therapeutics partenariat avec Roche\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/sarepta-therapeutics-announces-partnership-roche\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarepta Therapeutics Announces Partnership with Roche\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#website\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/\",\"name\":\"La Force dmd\",\"description\":\"Dystrophie musculaire de Duchenne\",\"publisher\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/laforcedmd.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#organization\",\"name\":\"La Force dmd\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/logo-la-force-dmd.jpg\",\"contentUrl\":\"https:\\\/\\\/laforcedmd.com\\\/wp-content\\\/uploads\\\/2022\\\/06\\\/logo-la-force-dmd.jpg\",\"width\":500,\"height\":125,\"caption\":\"La Force dmd\"},\"image\":{\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/laforcedmd.com\\\/#\\\/schema\\\/person\\\/aa9947f206c7912f07291299569bf4bf\",\"name\":\"Marie\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1a48fc20a72f762931838bcbd4de5af98782583e41b71b0b89e27d77b1de81e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1a48fc20a72f762931838bcbd4de5af98782583e41b71b0b89e27d77b1de81e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1a48fc20a72f762931838bcbd4de5af98782583e41b71b0b89e27d77b1de81e?s=96&d=mm&r=g\",\"caption\":\"Marie\"},\"url\":\"https:\\\/\\\/laforcedmd.com\\\/en\\\/author\\\/marie\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sarepta Therapeutics Announces Partnership with Roche - La Force dmd","description":"Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the US for its Investigational Micro-dystrophin Gene Therapy for DMD","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/","og_locale":"en_US","og_type":"article","og_title":"Sarepta Therapeutics Announces Partnership with Roche - La Force dmd","og_description":"Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the US for its Investigational Micro-dystrophin Gene Therapy for DMD","og_url":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/","og_site_name":"La Force dmd","article_published_time":"2019-12-23T11:11:30+00:00","article_modified_time":"2022-05-03T18:06:15+00:00","og_image":[{"width":815,"height":356,"url":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2019\/12\/Sarepta-Therapeutics-Announces-partnership-Roche.jpg","type":"image\/jpeg"}],"author":"Marie","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Marie","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/#article","isPartOf":{"@id":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/"},"author":{"name":"Marie","@id":"https:\/\/laforcedmd.com\/#\/schema\/person\/aa9947f206c7912f07291299569bf4bf"},"headline":"Sarepta Therapeutics Announces Partnership with Roche","datePublished":"2019-12-23T11:11:30+00:00","dateModified":"2022-05-03T18:06:15+00:00","mainEntityOfPage":{"@id":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/"},"wordCount":612,"commentCount":0,"publisher":{"@id":"https:\/\/laforcedmd.com\/#organization"},"image":{"@id":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/#primaryimage"},"thumbnailUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2019\/12\/Sarepta-Therapeutics-Announces-partnership-Roche.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/","url":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/","name":"Sarepta Therapeutics Announces Partnership with Roche - La Force dmd","isPartOf":{"@id":"https:\/\/laforcedmd.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/#primaryimage"},"image":{"@id":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/#primaryimage"},"thumbnailUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2019\/12\/Sarepta-Therapeutics-Announces-partnership-Roche.jpg","datePublished":"2019-12-23T11:11:30+00:00","dateModified":"2022-05-03T18:06:15+00:00","description":"Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the US for its Investigational Micro-dystrophin Gene Therapy for DMD","breadcrumb":{"@id":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/#primaryimage","url":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2019\/12\/Sarepta-Therapeutics-Announces-partnership-Roche.jpg","contentUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2019\/12\/Sarepta-Therapeutics-Announces-partnership-Roche.jpg","width":815,"height":356,"caption":"Sarepta Therapeutics partenariat avec Roche"},{"@type":"BreadcrumbList","@id":"https:\/\/laforcedmd.com\/en\/sarepta-therapeutics-announces-partnership-roche\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/laforcedmd.com\/en\/"},{"@type":"ListItem","position":2,"name":"Sarepta Therapeutics Announces Partnership with Roche"}]},{"@type":"WebSite","@id":"https:\/\/laforcedmd.com\/#website","url":"https:\/\/laforcedmd.com\/","name":"La Force dmd","description":"Dystrophie musculaire de Duchenne","publisher":{"@id":"https:\/\/laforcedmd.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/laforcedmd.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/laforcedmd.com\/#organization","name":"La Force dmd","url":"https:\/\/laforcedmd.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/laforcedmd.com\/#\/schema\/logo\/image\/","url":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2022\/06\/logo-la-force-dmd.jpg","contentUrl":"https:\/\/laforcedmd.com\/wp-content\/uploads\/2022\/06\/logo-la-force-dmd.jpg","width":500,"height":125,"caption":"La Force dmd"},"image":{"@id":"https:\/\/laforcedmd.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/laforcedmd.com\/#\/schema\/person\/aa9947f206c7912f07291299569bf4bf","name":"Marie","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f1a48fc20a72f762931838bcbd4de5af98782583e41b71b0b89e27d77b1de81e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f1a48fc20a72f762931838bcbd4de5af98782583e41b71b0b89e27d77b1de81e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f1a48fc20a72f762931838bcbd4de5af98782583e41b71b0b89e27d77b1de81e?s=96&d=mm&r=g","caption":"Marie"},"url":"https:\/\/laforcedmd.com\/en\/author\/marie\/"}]}},"_links":{"self":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts\/9399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/comments?post=9399"}],"version-history":[{"count":1,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts\/9399\/revisions"}],"predecessor-version":[{"id":11129,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/posts\/9399\/revisions\/11129"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/media\/9405"}],"wp:attachment":[{"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/media?parent=9399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/categories?post=9399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/laforcedmd.com\/en\/wp-json\/wp\/v2\/tags?post=9399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}